

## News Release

Newport Beach, CA – May 6, 2023



ImmunogenX®

# ImmunogenX Delivers Invited Talk at International Symposium

## Company CEO Presents Latest Results on Latiglutenase at Columbia University

ImmunogenX, a leader in the development of latiglutenase for treatment of celiac disease (CeD), was recognized once again for its ground breaking clinical results aimed at providing a first-to-market therapeutic treatment for CeD patients. The Columbia University Celiac Disease Center is a world's leading CeD facility and holds a regular International Symposium attended by the world's leading clinicians and key opinion leaders.

ImmunogenX is pleased that CEO, Jack Syage PhD, was invited to deliver a talk entitled "Update on Latiglutenase." The talk highlighted the Symposium's final session on Update on Drug Development lead by Dr. Peter HR Green, founder and head of the Columbia University Celiac Disease Center. Dr. Syage's talk was presented not only to an auditorium crowd but was also livestreamed to over 600 viewers.

## About ImmunogenX

ImmunogenX, Inc. is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel™) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. [www.immunogenx.com](http://www.immunogenx.com)

## For further information please contact

Matthew Dickason, MBA  
Chief Operating Officer  
(949) 679-0900  
[mdickason@immunogenx.com](mailto:mdickason@immunogenx.com)